All Type of News
The Forxiga complex ‘Xigduo’ is approved, having high competitiveness in the market
As the complex of the first domestic SGLT-2(Sodium-Glucose Transport Proteins) inhibitor, ‘Forxiga(dapagliflozin),’ is about to be launched, the industry has paid attention to it.
According to the Ministiry of Food a...
Boehringer Ingelheim won the lawsuit for Micardis PlusBoehringer Ingelheim Korea won a lawsuit for the formulation patent of Micardis Plus against the Ministry of Food and Drug Safety.
The 6th Division of the Seoul Administrative ...
|
Yuhan Corporation and GSK established the joint sales agreement for the influenza vaccineYuhan Corporation (President Jung-hee Lee) announced that it established a strategic partnership agreement for the co-marketing of the first domestic tetravalent influenza vacci...
|
“Doctors, please stay calm and cover medical fields against MERS”
The Korean Medical Association (President Moo-jin Chu, KMA) appealed to its members of doctors across the nation to stay calm in the MERS crisis and cover medical fields under the KMA guideline. To the Korean citizens...
Will differentiation of Daewoong Pharmaceutical be magnified in the Baraclude market?Daewoong Pharmaceutical will challenge to the type B liver cancer treatment.
According to the industry concerned, Daewoong Pharmaceutical and CTC Bio have been approved for gen...
|
Due to the prolonged MERS crisis, some pharmacies and wholesalers are making long faces with significantly lowered prescriptions
Since the MERS crisis seems to be prolonged, pharmacies and OTC distribution companies have been frustrated.
Due to the MERS crisis which has been visualized since the late-May, one of the common opinions is that mas...
Did only pharmacies enjoyed(?) the spread of MERS?
As demand for protective masks and hand sanitizers increases due to the rapid spread of Middle East Respiratory Syndrome(MERS), shortage of goods occurred.
According to the pharmaceutical distribution industry, the i...
The pharmaceutical industry with a long face due to MERS
MERS can be different even if it is the same type of a virus. The pharmaceutical industry, which often received reflective benefits from outbreaks of virus, has been rather making a long face since the emergence of ME...
The ethical issue of foreign companies to recruit personnel of a competing product
The act of poaching human resources of competing products between multinational pharmaceutical companies has been an issue once again.
The most well-known case is to replace the ‘same position’ of a multinational pha...
In regards to the insurance benefit expansion of high-price antibodies, is it ‘special treatment’ or ‘natural procedure’?
Antibodies are typically more expensive than regular drugs. Thus, a number of patients have requested higher insurance guarantee, but due to uncertainty of their effectiveness per price, antibodies are treatments rece...
